Finished product reference
Sodium Chloride
Solution, Drops · Ophthalmic · 5 % · 0.5 mL
- List code
- 50642
- Pharmacologic class
- Electrolyte replenisher / isotonic and hypertonic saline (multiple routes)
What it is and how it works
Sodium chloride provides sodium and chloride, the main extracellular electrolytes that determine extracellular fluid volume and osmolality. Isotonic (0.9%) solutions replace extracellular fluid; hypertonic solutions raise plasma sodium and osmolality or, applied locally, draw water osmotically from oedematous tissue (e.g. corneal oedema, airway mucus).
Indications
Intravenous: fluid and sodium replacement, hyponatraemia (hypertonic, under specialist care), vehicle for drug dilution. Irrigation: wound and bladder irrigation. Nasal: nasal dryness and congestion, nasal hygiene. Inhalation: diluent for nebulised drugs and hypertonic saline for airway clearance (e.g. cystic fibrosis). Ophthalmic hypertonic (2–5%) drops and ointment: corneal oedema.
Dosage and administration (summary)
Intravenous volume, concentration and rate are individualised to fluid and electrolyte status; topical, nasal, ophthalmic and inhalation products are used as directed for the specific product (e.g. hypertonic eye drops 1–2 drops several times daily).
Contraindications
Intravenous use: hypernatraemia, fluid overload and hyperchloraemia; hypertonic solutions in conditions where sodium load is hazardous. Irrigation solutions must not be injected.
Warnings and precautions
Monitor fluid balance and plasma electrolytes during intravenous therapy; use caution in heart failure, renal impairment, hypertension and oedema, and correct chronic hyponatraemia slowly to avoid osmotic demyelination. Hypertonic ophthalmic preparations may sting, and nebulised hypertonic saline may cause bronchospasm, so a bronchodilator may be needed beforehand.
Pregnancy
May be used in pregnancy with monitoring of fluid and electrolyte balance.
Storage and supply
Store below 25 °C; do not freeze; use single-use containers immediately after opening and discard multi-dose eye or nasal products within the period stated after opening.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Other presentations of the same active ingredient
- Injection, Solution · Intravenous · 20 % · 50 mL52793
- Injection, Solution · Intravenous · 5 % · 5 mL51928
- Injection, Solution · Intravenous · 5 % · 50 mL1148
- Injection, Solution · Parenteral · 0.45 % · 1000 mL1149
- Injection, Solution · Parenteral · 0.45 % · 250 mL6836
- Injection, Solution · Parenteral · 0.45 % · 500 mL2186
- Injection, Solution · Parenteral · 0.9 % · 10 mL8988
- Injection, Solution · Parenteral · 0.9 % · 100 mL13016
- Injection, Solution · Parenteral · 0.9 % · 1000 mL1141
- Injection, Solution · Parenteral · 0.9 % · 250 mL6417
- Injection, Solution · Parenteral · 0.9 % · 5 mL51815
- Injection, Solution · Parenteral · 0.9 % · 500 mL1144
- Ointment · Ophthalmic · 5 % · 5 g1110
- Solution · Irrigation · 0.9 % · 1000 mL1142
- Solution · Irrigation · 0.9 % · 2 L11545
- Solution · Irrigation · 0.9 % · 3 L1143
- Solution · Irrigation · 0.9 % · 500 mL1145
- Solution · Ophthalmic · 0.9 % · 5 mL13143
- Solution · Respiratory · 7 % · 4 mL52378
- Solution, Drops · Nasal · 0.65 % · 18 mL53246
- Solution, Drops · Nasal · 0.65 % · 20 mL1146
- Solution, Drops · Ophthalmic · 5 % · 10 mL1147
- Spray · Nasal · 0.65 % · 15 mL53229
- Spray · Nasal · 0.65 % · 20 mL7259
- Spray · Nasal · 0.65 % · 25 mL51911
- Spray · Nasal · 0.9 % · 150 mL53599
- Spray · Nasal · 0.9 % · 20 mL11633
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.